Stock Analysis
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis
Bio-Rad Laboratories, Inc. (BIO) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Bio-Rad Laboratories, Inc. (BIO) currently has an AIQ Score of 73/100, indicating a bullish setup. Value is the strongest factor at 80/100. Quality is the weakest current factor at 61/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
BIO at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $370.17 |
| AIQ Score | 73/100 |
| Overall View | Bullish |
| Technical Analysis Consensus | Sell |
| Market Cap | $9.81B |
| P/E Ratio (TTM) | 9.39 |
| Forward P/E | — |
| EPS (Q3 FY2026) | $17.13 |
| Revenue (Q3 FY2026) | $656.4M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.73 |
| Volume | 460.48K |
| 52-week range | $236.73-$396.23 |
| RSI 14 | 45.43 |
| 50-Day SMA | $372.95 |
| 200-Day SMA | $316.99 |
| Analyst Price Target | — |
| Next Earnings | Feb 11, 2027 |
BIOBio-Rad Laboratories, Inc.
Healthcare / Medical - Devices
Leader
Sector Leader
Latest quote
- Momentum79
- Value80
- Quality61
- Risk resilience74
- Sentiment—
BIO Stock Analysis Summary
Bio-Rad Laboratories, Inc. (BIO) currently has an AIQ Score of 73/100, indicating a bullish setup. Value is the strongest factor at 80/100. Quality is the weakest current factor at 61/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bullish regime, BIO has AIQ Score of 73/100 with Value base of 80/100 and fading Quality at 61/100. Wait for component alignment before adding exposure.
Healthcare · 3.34% stock move · BIO classified in Medical - Devices.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is BIO Bullish or Bearish Right Now?
BIO currently has a bullish overall setup. Value is the strongest factor at 80/100, while Quality is weakest at 61/100. The current evidence suggests a constructive setup.
- - Momentum is constructive at 79/100.
- - Risk Resilience is supportive at 74/100.
- - Technical consensus has more sell votes than buy votes (26 vs 13).
Current Consensus
BIO's Technical Analysis Consensus is currently Sell, with 13 buy, 7 neutral, and 26 sell votes. BIO's 14-day RSI is 45.43, which places the stock in a neutral momentum range. BIO's beta is 0.73, indicating lower market sensitivity than the broad market.
What Changed in BIO?
The largest recent change in BIO is Momentum moving down by 5.0 points over the available 7-day comparison window. Value remains the strongest visible factor.
What Would Change the BIO Outlook?
The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
BIO Decision Framework
Public evidence layers, setup checks, and risk context for Bio-Rad Laboratories, Inc..
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis
Bio-Rad Laboratories, Inc. has an AIQ Score of 73/100 in a Bullish regime. Value is strongest at 80/100. Beta is 0.73, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | BIO is in a Bullish AIQ regime with score 73/100. |
| Signal Conflict | The primary conflict is that value leads at 80/100 while quality lags at 61/100. |
| Factor Evidence | Momentum 79/100 · Value 80/100 · Quality 61/100 · Risk 74/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Value is the strongest factor at 80/100.
Momentum is 79/100 and RSI (14) is 45.4.
BIO is in a Bullish regime at 73/100.
Risk factor is 74/100 with beta 0.73 and annual volatility 36.18%.
Current conflict: value leads at 80/100 while quality lags at 61/100.
BIO Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
BIO Fundamentals
BIO valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
BIO Technical Analysis
BIO technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
BIO Stock Catalysts
Track BIO earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
BIO Dividend Analysis
BIO dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
BIO Financial Data
BIO revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
BIO Risk Analysis
BIO volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
BIO Stock News
BIO stock news, market tone, recent headlines, and catalyst context.
BIO vs Medical - Devices Peers
Current peer cohort: BIO · BRKR · CNMD · ESTA · GKOS. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| BIO Current stock | 73/100 | 80/100 | 79/100 | 74/100 | 0.47 | 36.18% | Current |
| BRKR Bruker Corporation | 64/100 | 53/100 | 83/100 | 44/100 | 0.89 | 59.79% | BIO vs BRKR |
| CNMD CONMED Corporation | 71/100 | 84/100 | 74/100 | 58/100 | 0.48 | 46.99% | BIO vs CNMD |
| ESTA Establishment Labs Holdings Inc. | 48/100 | 32/100 | 58/100 | 47/100 | 0.35 | 49.89% | BIO vs ESTA |
| GKOS Glaukos Corporation | 65/100 | 30/100 | 90/100 | 57/100 | 1.83 | 61.36% | BIO vs GKOS |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 18, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for BIO: historical return with reinvested dividends, dollar-cost averaging (DCA) backtest and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 19, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching BIO
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for BIO
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
BIO Stock FAQ
What is BIO stock price today?
Bio-Rad Laboratories, Inc.'s current stock price is $370.17. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is BIO bullish or bearish right now?
BIO's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is BIO's market cap?
BIO's market cap is $9.81B based on the latest completed market-close snapshot from Nov 18, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is BIO's current P/E ratio?
BIO's current P/E ratio is 9.39 based on the latest completed market-close snapshot from Nov 18, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is BIO's RSI?
BIO's 14-day RSI is 45.43 based on the latest completed market-close snapshot from Nov 18, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is BIO above its 50-day and 200-day moving averages?
BIO is -1.77% from its 50-day SMA and 15.57% from its 200-day SMA based on the latest completed market-close snapshot from Nov 18, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is BIO's next earnings date?
BIO's next earnings date is currently listed as Feb 11, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does BIO pay a dividend?
BIO's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 18, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.